Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses (2016 - 2018)

Vanda Pharmaceuticals' Other Accumulated Expenses history spans 8 years, with the latest figure at $2.0 million for Q1 2018.

  • On a quarterly basis, Other Accumulated Expenses rose 8.93% to $2.0 million in Q1 2018 year-over-year; TTM through Mar 2018 was $2.0 million, a 8.93% increase, with the full-year FY2017 number at $2.0 million, up 75.84% from a year prior.
  • Other Accumulated Expenses hit $2.0 million in Q1 2018 for Vanda Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for VNDA hit a ceiling of $2.0 million in Q1 2018 and a floor of $614000.0 in Q1 2014.
  • Historically, Other Accumulated Expenses has averaged $1.5 million across 5 years, with a median of $1.6 million in 2015.
  • Biggest five-year swings in Other Accumulated Expenses: soared 4555.56% in 2014 and later tumbled 32.66% in 2016.
  • Tracing VNDA's Other Accumulated Expenses over 5 years: stood at $2.0 million in 2014, then dropped by 16.63% to $1.7 million in 2015, then tumbled by 32.66% to $1.1 million in 2016, then soared by 75.84% to $2.0 million in 2017, then rose by 1.5% to $2.0 million in 2018.
  • Business Quant data shows Other Accumulated Expenses for VNDA at $2.0 million in Q1 2018, $2.0 million in Q4 2017, and $1.9 million in Q3 2017.